HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deacon, C. F. Search for Related Content PubMed PubMed Citation Articles by Deacon, C. F. Social Bookmarking                What's this?

Therapeutic Strategies Based on Glucagon-Like Peptide 1

Department of Medical Physiology, The Panum Institute, Copenhagen, Denmark

Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on the pancreatic ß-cells, and inhibitory effects on gastrointestinal secretion and motility, which combine to lower plasma glucose and reduce glycemic excursions. Furthermore, via its ability to enhance satiety, GLP-1 reduces food intake, thereby limiting weight gain, and may even cause weight loss. Taken together, these actions give GLP-1 a unique profile, considered highly desirable for an antidiabetic agent, particularly since the glucose dependency of its antihyperglycemic effects should minimize any risk of severe hypoglycemia. However, its pharmacokinetic/pharmacodynamic profile is such that native GLP-1 is not therapeutically useful. Thus, while GLP-1 is most effective when administered continuously, single subcutaneous injections have short-lasting effects. GLP-1 is highly susceptible to enzymatic degradation in vivo, and cleavage by dipeptidyl peptidase IV (DPP-IV) is probably the most relevant, since this occurs rapidly and generates a noninsulinotropic metabolite. Strategies for harnessing GLP-1’s therapeutic potential, based on an understanding of factors influencing its metabolic stability and pharmacokinetic/pharmacodynamic profile, have therefore been the focus of intense research in both academia and the pharmaceutical industry. Such strategies include DPP-IV–resistant GLP-1 analogs and selective enzyme inhibitors to prevent in vivo degradation of the peptide.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Lerche, B. Brock, J. Rungby, H. E. Botker, N. Moller, A. Rodell, B. M. Bibby, J. J. Holst, O. Schmitz, and A. Gjedde Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans Diabetes, February 1, 2008; 57(2): 325 - 331. [Abstract] [Full Text] [PDF]

				H. Chahal and T.A. Chowdhury Gliptins: a new class of oral hypoglycaemic agent QJM, November 1, 2007; 100(11): 671 - 677. [Abstract] [Full Text] [PDF]

				L. Simonsen, S. Pilgaard, C. Orskov, M. M. Rosenkilde, B. Hartmann, J. J. Holst, and C. F. Deacon Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G288 - G295. [Abstract] [Full Text] [PDF]

				B. Laferrere, S. Heshka, K. Wang, Y. Khan, J. McGinty, J. Teixeira, A. B. Hart, and B. Olivan Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux-en-Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes Diabetes Care, July 1, 2007; 30(7): 1709 - 1716. [Abstract] [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				R. Iakoubov, A. Izzo, A. Yeung, C. I. Whiteside, and P. L. Brubaker Protein Kinase C{zeta} Is Required for Oleic Acid-Induced Secretion of Glucagon-Like Peptide-1 by Intestinal Endocrine L Cells Endocrinology, March 1, 2007; 148(3): 1089 - 1098. [Abstract] [Full Text] [PDF]

				D. Hinnen, L. L. Nielsen, A. Waninger, and P. Kushner Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes J Am Board Fam Med, November 1, 2006; 19(6): 612 - 620. [Abstract] [Full Text] [PDF]

				C. Zhang, L. Qi, D. J. Hunter, J. B. Meigs, J. E. Manson, R. M. van Dam, and F. B. Hu Variant of Transcription Factor 7-Like 2 (TCF7L2) Gene and the Risk of Type 2 Diabetes in Large Cohorts of U.S. Women and Men Diabetes, September 1, 2006; 55(9): 2645 - 2648. [Abstract] [Full Text] [PDF]

				B. D. Green, K. S. Lavery, N. Irwin, F. P. M. O'Harte, P. Harriott, B. Greer, C. J. Bailey, and P. R. Flatt Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic beta-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 914 - 921. [Abstract] [Full Text] [PDF]

				G. A. Herman, A. Bergman, F. Liu, C. Stevens, A. Q. Wang, W. Zeng, L. Chen, K. Snyder, D. Hilliard, M. Tanen, et al. Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP-4 Inhibitor Sitagliptin in Middle-Aged Obese Subjects. J. Clin. Pharmacol., August 1, 2006; 46(8): 876 - 886. [Abstract] [Full Text] [PDF]

				R. Hood, V. Valentine, S. Mac, and W. H Polonsky Use of Exenatide in Patients With Type 2 Diabetes Diabetes Spectr, July 1, 2006; 19(3): 181 - 186. [Abstract] [Full Text] [PDF]

				P. T. Gunnarsson, M. S. Winzell, C. F. Deacon, M. O. Larsen, K. Jelic, R. D. Carr, and B. Ahren Glucose-Induced Incretin Hormone Release and Inactivation Are Differently Modulated by Oral Fat and Protein in Mice Endocrinology, July 1, 2006; 147(7): 3173 - 3180. [Abstract] [Full Text] [PDF]

				J. J. Meier, A. Gethmann, M. A. Nauck, O. Gotze, F. Schmitz, C. F. Deacon, B. Gallwitz, W. E. Schmidt, and J. J. Holst The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1118 - E1123. [Abstract] [Full Text] [PDF]

				J. A. Koehler and D. J. Drucker Activation of glucagon-like Peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes, May 1, 2006; 55(5): 1369 - 1379. [Abstract] [Full Text] [PDF]

				M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]

				L. A. Nikolaidis, D. Elahi, Y.-T. Shen, and R. P. Shannon Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2401 - H2408. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				Y. Li, X. Cao, L.-X. Li, P. L. Brubaker, H. Edlund, and D. J. Drucker {beta}-Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1 Diabetes, February 1, 2005; 54(2): 482 - 491. [Abstract] [Full Text] [PDF]

				C. W. le Roux and S. R. Bloom Why Do Patients Lose Weight after Roux-en-Y Gastric Bypass? J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 591 - 592. [Full Text] [PDF]